Immune Checkpoint Therapy in Liver Cancer: Current Evidence, Underlying Biology, and What's Next

Dear Colleagues,

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. In recent years, the management of patients with HCC has changed considerably, due to improvements in molecular biology knowledge and the introduction of immunotherapy. To date, systemic therapy is authorized in patients with advanced HCC.

Moreover, there is increasing evidence that immunotherapy could also play a role as an adjuvant therapy in intermediate stages, pre-transplant downstaging, or post-liver-transplant recurrence.

Despite improvements over the years, these indications are not fully endorsed or stated in the guidelines due to the absence of studies and trials.

This Special Issue aims to explore the field of immunotherapy in liver cancer, evaluating innovative aspects and developing those that are poorly defined or already addressed. A first objective will be to gather evidence on the potential role of immunotherapy in all stages, not just the advanced stage.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the role of immunotherapy in all stages of liver cancer and in combination with other treatment techniques. In addition, interesting data may concern the effect of immunotherapy on the tumor microenvironment.

We look forward to receiving insightful contributions.

Dr. Luca Marzi
Dr. Rodolfo Sacco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.